The Melanocortin Receptor System
The melanocortin system comprises five G-protein-coupled receptors (MC1R through MC5R) and a family of endogenous peptide ligands derived from the proopiomelanocortin (POMC) precursor protein. POMC is cleaved into several biologically active fragments including adrenocorticotropic hormone (ACTH), alpha-MSH, beta-MSH, and gamma-MSH, each with distinct receptor selectivity profiles. Melanocortin receptors are expressed throughout the body and are involved in diverse physiological processes including pigmentation, energy balance, immune function, and CNS signaling.
MC1R mediates the pigmentation effects of melanocortins in melanocytes. MC2R is the primary ACTH receptor in the adrenal gland. MC3R and MC4R are expressed predominantly in the hypothalamus and other CNS regions and are involved in energy homeostasis, feeding behavior, and sexual function research. MC5R is expressed in exocrine glands and has been studied in the context of glandular secretion. For PT-141 research, MC3R and MC4R are the primary receptor targets of interest.
Alpha-MSH, the endogenous nonselective agonist at MC1R, MC3R, and MC4R, has been a central reference compound in melanocortin pharmacology research for decades. Synthetic analogs such as Melanotan I (afamelanotide), Melanotan II, and PT-141 were developed to probe melanocortin receptor subtypes with varying selectivity and stability profiles.
- MC1R: melanocyte pigmentation.
- MC2R: adrenal ACTH receptor.
- MC3R: hypothalamic energy balance and feeding.
- MC4R: hypothalamic sexual function, energy balance, and reward signaling.
- MC5R: exocrine gland function.
PT-141 As A Melanocortin Receptor Agonist
PT-141 binds and activates MC3R and MC4R with high affinity. Its development from Melanotan II involved cyclization of the linear peptide to improve metabolic stability, and the free carboxyl terminus in PT-141 reduces the tanning side effects associated with MC1R activation that were observed with Melanotan II. This makes PT-141 a more selective tool for studying MC3R/MC4R-mediated signaling without strong concomitant pigmentation effects in cellular models.
In receptor-binding studies, PT-141 has been characterized using radioligand competition assays and cAMP accumulation assays in cells transfected with individual melanocortin receptor subtypes. These assays provide Ki and EC50 values that define its pharmacological profile. In vitro receptor characterization of this type is standard practice for any compound under investigation in G-protein-coupled receptor research.
The signal transduction pathway downstream of MC4R involves Gs-protein coupling, adenylyl cyclase activation, and cyclic AMP accumulation. In neural cell models and hypothalamic preparations, MC4R activation by melanocortin agonists has been studied in the context of energy balance regulation, neuropeptide release, and synaptic modulation.
Sexual Behavior Pharmacology Research
A significant body of preclinical research has examined the role of MC4R in sexual behavior in rodent models. Studies using selective MC4R agonists and antagonists, as well as MC4R knockout mice, have established that MC4R signaling in specific hypothalamic nuclei is associated with pro-erectile and pro-sexual behavioral responses in male rodents. PT-141 has been studied as a pharmacological tool in these models because of its MC4R agonist activity.
In female rodent models, melanocortin agonism has been studied in the context of lordosis behavior, a posture associated with sexual receptivity that is regulated by hypothalamic circuits. These studies use brain-region-specific injection paradigms and behavioral scoring to characterize the role of melanocortin signaling in sexual behavior circuits.
The research findings in animal models contributed to clinical investigations of PT-141 (Bremelanotide), which received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women. The existence of an approved pharmaceutical form of Bremelanotide does not alter the Research Use Only status of PT-141 supplied as a research peptide, which is for in vitro laboratory research only.
Research Use Only Status
PT-141 supplied as a research peptide is for in vitro laboratory research only, regardless of the existence of an FDA-approved pharmaceutical form of the compound. The research peptide and the pharmaceutical product occupy different regulatory categories as described by the Research Use Only designation. Researchers should consult the primary literature for in vitro receptor pharmacology and signaling study protocols and should verify purity and identity through batch-specific Certificate of Analysis documentation before use.
Research Use Only: This guide is informational and describes research-context handling of compounds intended strictly for in vitro laboratory research. Products are not for human or animal consumption, ingestion, or injection, and are not FDA-approved. Nothing here is medical, clinical, or dosing advice.